Ad
related to: dabrafenib trametinib melanomabenchmarkguide.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
Dabrafenib is indicated as a single agent for the treatment of people with unresectable or metastatic melanoma with BRAF V600E mutation. [2] Dabrafenib is indicated, in combination with trametinib, for BRAF V600E-positive unresectable or metastatic melanoma, metastatic non-small cell lung cancer, metastatic anaplastic thyroid cancer, and unresectable or metastatic solid tumors.
When taken in combination with dabrafenib the most common side effects include fever, tiredness, nausea, chills, headache, diarrhea, vomiting, joint pain and rash. [5] In May 2013, trametinib was approved as a single-agent by the US Food and Drug Administration for the treatment of people with V600E mutated metastatic melanoma.
Other ph 3 clinical trials underway include uveal melanoma (failed), and differentiated thyroid carcinoma. Trametinib (GSK1120212), FDA-approved to treat BRAF-mutated melanoma. Also studied in combination with BRAF inhibitor dabrafenib to treat BRAF-mutated melanoma.
Braf inhibitors (vemurafenib, dabrafenib, LGX818) used to treat metastatic melanoma that harbors BRAF V600E mutation; MEK inhibitors (trametinib, MEK162) are used in experiments, often in combination with BRAF inhibitors to treat melanoma; CDK inhibitors, e.g. PD-0332991, LEE011 in clinical trials; Hsp90 inhibitors, some in clinical trials
Melanoma is the most dangerous type of skin cancer; ... (PFS) times. The therapy combination of dabrafenib and trametinib has a 3-year PFS of 23%, and 5-year PFS of 13%.
Polypoid melanoma is a rare cutaneous condition, ... such as vemurafenib and dabrafenib; and an MEK inhibitor trametinib. ...
Through clinical trials, Jeffrey Weber, director of the Donald A. Adam Comprehensive Melanoma Research Center at Moffitt, and researchers at Moffitt Cancer Center discovered two monotherapy drugs – Mekinist (trametinib) and Tafinlar (dabrafenib) – can be safely combined to overcome or delay treatment resistance for a large percentage of ...
Dabrafenib [1] Novartis Pharmaceuticals: melanoma with BRAF V600E or V600K mutations Trametinib [1] Novartis Pharmaceuticals: melanoma with BRAF V600E or V600K mutations Dabrafenib [1] Novartis Pharmaceuticals: anaplastic thyroid cancer with BRAF V600E mutation Trametinib [1] Novartis Pharmaceuticals: anaplastic thyroid cancer with BRAF V600E ...
Ad
related to: dabrafenib trametinib melanomabenchmarkguide.com has been visited by 10K+ users in the past month